QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 25, no. 5 (2006): 1309-1317
doi: 10.1377/hlthaff.25.5.1309
© 2006 by Project HOPE
 
New Online
 * Pay Cuts For Medicare Docs
 * Access To Care Woes
 * Public Coverage More Efficient
 * Empowering Consumers
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Online Technical Appendix
* Submit a response to this article
* Alert me when this article is cited
* Alert me when eLetters are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Reed, S. D.
* Articles by Schulman, K. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Reed, S. D.
* Articles by Schulman, K. A.
Related Collections
* Insurance Market
* Access To Care
* Business Of Health
* Consumer Issues
* Evidence-Based Medicine
* Insurance Coverage
* International Issues
* Pharmaceuticals
* Quality Of Care
* Research And Technology
* Health Spending

Evolution & Future

How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation

Shelby D. Reed, Robert M. Califf and Kevin A. Schulman

Changes in the economics of product development resulting from heightened safety regulations could have a sizable negative impact on drug and biotechnology companies’ decisions about investing in innovation. We developed a model to compare the potential economic effects of pre- and postmarketing strategies to identify safety problems with new drugs. Although expanding Phase III clinical testing and postmarketing safety surveillance are not perfect substitutes, our findings suggest that even a large increase in funding for the latter will have a relatively small adverse impact on investment decisions by drug companies and venture capital firms, compared with the former.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?




Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2006 Project HOPE–The People-to-People Organization
Terms and Policies